TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Age-Related Eye Disease Study 2 (AREDS2): A Multi-center, Randomized Trial of Lutein, Zeaxanthin and Omega-3 Long-Chain Polyunsaturated Fatty Acids (Docosahexaenoic Acid [DHA] and Eicosapentaenoic Acid [EPA]) in Age-Related Macular Degeneration
Brief Summary: Oral supplementation with the Age-Related Eye Disease Study (AREDS) formulation (antioxidant vitamins C and E, beta carotene, and zinc) has been shown to reduce the risk of progression to advanced age-related macular degeneration (AMD). Observational data suggest that increased dietary intake of lutein + zeaxanthin (carotenoids), omega-3 long-chain polyunsaturated fatty acids (docosahexaenoic acid \[DHA\] + eicosapentaenoic acid \[EPA\]), or both might further reduce this risk. AREDS2 was designed to test whether adding lutein + zeaxanthin, DHA + EPA, or lutein + zeaxanthin and DHA + EPA to the AREDS formulation might further reduce the risk of progression to advanced AMD. A secondary goal was to test the effects of eliminating beta carotene and reducing zinc dose in the AREDS formulation.


Options:
A: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
B: Intervention Type: PROCEDURE; Name: Subfoveal Choroidal Neovascularization Removal; Assigned to Arm(s): N/A
C: Arm Label: bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): bevacizumab
D: Arm Label: Lutein/Zeaxanthin; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lutein/zeaxanthin | Arm Label: DHA/EPA; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: DHA/EPA | Arm Label: Lutein/Zeaxanthin + DHA/EPA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lutein/zeaxanthin and DHA/EPA | Arm Label: Placebo/Control; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Lutein/zeaxanthin; Assigned to Arm(s): Lutein/Zeaxanthin | Intervention Type: DIETARY_SUPPLEMENT; Name: DHA/EPA; Assigned to Arm(s): DHA/EPA | Intervention Type: DRUG; Name: Lutein/zeaxanthin and DHA/EPA; Assigned to Arm(s): Lutein/Zeaxanthin + DHA/EPA

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cluster Randomised Controlled Trial of the Effect of the Introduction of an Acute Wheeze/Asthma Integrated Care Pathway on Patient Outcome
Brief Summary: Integrated care pathways (ICP) coalesce medical and nursing work practices, unifying and directing care in line with current best practice and guidelines. We wish to examine the introduction of an ICP for children with wheeze/asthma admitted to our hospital. We will determine whether more rigid, but guided care results in faster recovery, quicker discharge with better education and fewer prescribing errors, but also determine whether staff feel alienated by the rigidity of practice, and parents perceive any benefit to the changes introduced.This will be a cluster randomised trial (random weeks) of standard or ICP care in 180 patients admitted to Sick Kids with wheeze/asthma. Parents will be asked to complete a questionnaire on admission and contacted at 10-14 days post discharge and asked to recall education provided at discharge; no other patient or parent intervention will be required.It is expected to take 40 weeks to recruit 180 patients.


Options:
A: Intervention Type: DEVICE; Name: Integrated Care Pathway; Assigned to Arm(s): N/A
B: Arm Label: Montelukast 7 mg; Type: EXPERIMENTAL; Interventions: Drug: montelukast sodium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: montelukast sodium; Assigned to Arm(s): Montelukast 7 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: placebo (unspecified) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: montelukast sodium | Intervention Type: DRUG; Name: montelukast sodium; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Comparator: placebo (unspecified); Assigned to Arm(s): 1
D: Arm Label: A1; Type: ACTIVE_COMPARATOR; Interventions: Drug: montelukast | Arm Label: A2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: montelukast; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of a Decision Aid for Adult Cystic Fibrosis Patients Considering Bilateral Lung Transplantation
Brief Summary: In 2006, the International Patient Decision Aids Collaboration (IPDAS) reached agreement on criteria for evaluation. Accordingly, the primary outcome is 'decision quality' 3 weeks after using the decision aid. Decision quality is defined as the extent to which a patient decision aid improves the match between the chosen option and the features that matter most to the informed patient. Measures include: a) patients' knowledge of essential facts \[options, benefits, harms, and outcome probabilities\]; and b. the congruence between the option chosen and patients' informed values regarding benefits and risks.

In the past twenty years lung transplantation has become the most widely accepted option of treating cystic fibrosis patients with severe lung disease. Lung transplantation can be a good experience for many patients, improving their quality of life and their survival. However there are potential risks of lung transplantation including infection, organ rejection and early death. Cystic fibrosis patients are often faced with making a choice of whether to be referred for lung transplantation when they are very sick and there is the immediate need to survive. Our group has developed a tool called a decision aid which we hope will assist the patient and family in making this choice. The decision aid guides the patient through a series of steps where they weigh the benefits and risks of being referred for lung transplantation and the benefits and risks of receiving 'usual care' without the option of referral.


Options:
A: Arm Label: Vascular Access Patient Decision Aid; Type: EXPERIMENTAL; Interventions: Behavioral: Vascular Access Decision Aid | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Vascular Access Decision Aid; Assigned to Arm(s): Vascular Access Patient Decision Aid
B: Intervention Type: BEHAVIORAL; Name: Decision Aid; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Heart to Heart (Web-Based Decision Aid), Behavioral: Physician Education Session | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Heart to Heart (Web-Based Decision Aid); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Physician Education Session; Assigned to Arm(s): 1
D: Arm Label: 1; Type: OTHER; Interventions: Behavioral: Cognitive Behavioral Intervention | Arm Label: 2; Type: OTHER; Interventions: Behavioral: Office System Redesign Intervention | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Intervention; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Office System Redesign Intervention; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of a Decision Aid for Adult Cystic Fibrosis Patients Considering Bilateral Lung Transplantation
Brief Summary: In 2006, the International Patient Decision Aids Collaboration (IPDAS) reached agreement on criteria for evaluation. Accordingly, the primary outcome is 'decision quality' 3 weeks after using the decision aid. Decision quality is defined as the extent to which a patient decision aid improves the match between the chosen option and the features that matter most to the informed patient. Measures include: a) patients' knowledge of essential facts \[options, benefits, harms, and outcome probabilities\]; and b. the congruence between the option chosen and patients' informed values regarding benefits and risks.

In the past twenty years lung transplantation has become the most widely accepted option of treating cystic fibrosis patients with severe lung disease. Lung transplantation can be a good experience for many patients, improving their quality of life and their survival. However there are potential risks of lung transplantation including infection, organ rejection and early death. Cystic fibrosis patients are often faced with making a choice of whether to be referred for lung transplantation when they are very sick and there is the immediate need to survive. Our group has developed a tool called a decision aid which we hope will assist the patient and family in making this choice. The decision aid guides the patient through a series of steps where they weigh the benefits and risks of being referred for lung transplantation and the benefits and risks of receiving 'usual care' without the option of referral.


Options:
A: Intervention Type: BEHAVIORAL; Name: Decision Aid; Assigned to Arm(s): N/A
B: Arm Label: SMS and Internet; Type: EXPERIMENTAL; Interventions: Behavioral: MD2ME | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: MD2ME; Assigned to Arm(s): SMS and Internet
C: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
D: Arm Label: Usual Support Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual-Support | Arm Label: Enhanced Support Group; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Support | Intervention Type: BEHAVIORAL; Name: Enhanced Support; Assigned to Arm(s): Enhanced Support Group | Intervention Type: BEHAVIORAL; Name: Usual-Support; Assigned to Arm(s): Usual Support Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An International, Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group, Study of 3-month or 6-month Treatment With SSR126517E (3.0 mg s.c. Once-weekly) Versus Oral INR-adjusted Warfarin in the Treatment of Patients With Symptomatic Pulmonary Embolism With or Without Symptomatic Deep Venous Thrombosis
Brief Summary: Objectives are to evaluate whether idrabiotaparinux sodium (SSR126517E) is as least as effective as a standard warfarin treatment to prevent recurrence of venous thromboembolic events (VTE) in patients with symptomatic pulmonary embolism (PE) with or without symptomatic deep venous thrombosis (DVT) and to assess its safety (bleedings) versus warfarin.


Options:
A: Arm Label: Fondaparinux; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fondaparinux | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Fondaparinux; Assigned to Arm(s): Fondaparinux | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: SR34006; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: (LMW)heparin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Warfarin VKA; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Acenocoumarol VKA; Assigned to Arm(s): N/A
C: Arm Label: Fondaparinux 2.5mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fondaparinux 2.5mg or placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Fondaparinux 2.5mg or placebo | Intervention Type: DRUG; Name: Fondaparinux 2.5mg or placebo; Assigned to Arm(s): Fondaparinux 2.5mg, Placebo
D: Arm Label: Idrabiotaparinux; Type: EXPERIMENTAL; Interventions: Drug: Idrabiotaparinux sodium, Drug: Avidin, Drug: Placebo (for warfarin), Drug: Enoxaparin | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin, Drug: Placebo (for idrabiotaparinux sodium), Drug: Avidin, Drug: Enoxaparin | Intervention Type: DRUG; Name: Idrabiotaparinux sodium; Assigned to Arm(s): Idrabiotaparinux | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Placebo (for idrabiotaparinux sodium); Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Avidin; Assigned to Arm(s): Idrabiotaparinux, Warfarin | Intervention Type: DRUG; Name: Placebo (for warfarin); Assigned to Arm(s): Idrabiotaparinux | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Idrabiotaparinux, Warfarin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An International, Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group, Study of 3-month or 6-month Treatment With SSR126517E (3.0 mg s.c. Once-weekly) Versus Oral INR-adjusted Warfarin in the Treatment of Patients With Symptomatic Pulmonary Embolism With or Without Symptomatic Deep Venous Thrombosis
Brief Summary: Objectives are to evaluate whether idrabiotaparinux sodium (SSR126517E) is as least as effective as a standard warfarin treatment to prevent recurrence of venous thromboembolic events (VTE) in patients with symptomatic pulmonary embolism (PE) with or without symptomatic deep venous thrombosis (DVT) and to assess its safety (bleedings) versus warfarin.


Options:
A: Intervention Type: DRUG; Name: SR34006 (idraparinux sodium) Injection; Assigned to Arm(s): N/A
B: Arm Label: Fondaparinux; Type: EXPERIMENTAL; Interventions: Drug: Fondaparinux sodium | Arm Label: unfractionated heparin; Type: OTHER; Interventions: Drug: unfractionated heparin (UFH) | Intervention Type: DRUG; Name: Fondaparinux sodium; Assigned to Arm(s): Fondaparinux | Intervention Type: DRUG; Name: unfractionated heparin (UFH); Assigned to Arm(s): unfractionated heparin
C: Arm Label: Idrabiotaparinux; Type: EXPERIMENTAL; Interventions: Drug: Idrabiotaparinux sodium, Drug: Avidin, Drug: Placebo (for warfarin), Drug: Enoxaparin | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin, Drug: Placebo (for idrabiotaparinux sodium), Drug: Avidin, Drug: Enoxaparin | Intervention Type: DRUG; Name: Idrabiotaparinux sodium; Assigned to Arm(s): Idrabiotaparinux | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Placebo (for idrabiotaparinux sodium); Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Avidin; Assigned to Arm(s): Idrabiotaparinux, Warfarin | Intervention Type: DRUG; Name: Placebo (for warfarin); Assigned to Arm(s): Idrabiotaparinux | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Idrabiotaparinux, Warfarin
D: Intervention Type: DRUG; Name: Fondaparinux; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ECLIPSE Trial - Ensure's Vascular Closure Device Speeds Hemostasis Trial
Brief Summary: The purpose of this study is to determine whether the Ensure Medical Vascular Closure Device is more effective than standard manual compression at sealing the puncture made in the femoral artery following a cardiac or peripheral diagnostic or interventional procedure while maintaining the same level of safety.


Options:
A: Arm Label: Standard EVAR (IntuiTrak); Type: ACTIVE_COMPARATOR; Interventions: Device: SEVAR (IntuiTrak) | Arm Label: PEVAR (ProGlide closure); Type: EXPERIMENTAL; Interventions: Device: PEVAR (ProGlide closure) | Arm Label: PEVAR (ProstarXL closure); Type: EXPERIMENTAL; Interventions: Device: PEVAR (Prostar XL closure) | Intervention Type: DEVICE; Name: PEVAR (ProGlide closure); Assigned to Arm(s): PEVAR (ProGlide closure) | Intervention Type: DEVICE; Name: SEVAR (IntuiTrak); Assigned to Arm(s): Standard EVAR (IntuiTrak) | Intervention Type: DEVICE; Name: PEVAR (Prostar XL closure); Assigned to Arm(s): PEVAR (ProstarXL closure)
B: Arm Label: Manual Compression; Type: ACTIVE_COMPARATOR; Interventions: Other: Manual Compression | Arm Label: Vascular Closure Device; Type: EXPERIMENTAL; Interventions: Device: Vascular Closure Device | Intervention Type: OTHER; Name: Manual Compression; Assigned to Arm(s): Manual Compression | Intervention Type: DEVICE; Name: Vascular Closure Device; Assigned to Arm(s): Vascular Closure Device
C: Arm Label: FemoSeal®; Type: EXPERIMENTAL; Interventions: Device: FemoSeal® | Arm Label: ExoSeal®; Type: EXPERIMENTAL; Interventions: Device: ExoSeal® | Arm Label: Manual compression; Type: ACTIVE_COMPARATOR; Interventions: Other: Manual compression | Intervention Type: DEVICE; Name: FemoSeal®; Assigned to Arm(s): FemoSeal® | Intervention Type: DEVICE; Name: ExoSeal®; Assigned to Arm(s): ExoSeal® | Intervention Type: OTHER; Name: Manual compression; Assigned to Arm(s): Manual compression
D: Arm Label: FemoSeal®; Type: EXPERIMENTAL; Interventions: Device: FemoSeal® | Arm Label: Manual compression; Type: ACTIVE_COMPARATOR; Interventions: Other: Manual compression | Intervention Type: DEVICE; Name: FemoSeal®; Assigned to Arm(s): FemoSeal® | Intervention Type: OTHER; Name: Manual compression; Assigned to Arm(s): Manual compression

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy RSV and PIV3 Seropositive 1-9 Year-Old Children
Brief Summary: This is a randomized, double-blind, placebo-controlled, dose-escalation, Phase 1, multi-center study to evaluate the safety, tolerability, immunogenicity, and viral shedding of MEDI-534 in healthy children 1-9 years of age who are seropositive for respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) at screening.


Options:
A: Arm Label: RSV LID ΔM2-2 Vaccine; Type: EXPERIMENTAL; Interventions: Biological: RSV LID ΔM2-2 Vaccine | Arm Label: Placebo Vaccine; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo Vaccine | Intervention Type: BIOLOGICAL; Name: RSV LID ΔM2-2 Vaccine; Assigned to Arm(s): RSV LID ΔM2-2 Vaccine | Intervention Type: BIOLOGICAL; Name: Placebo Vaccine; Assigned to Arm(s): Placebo Vaccine
B: Arm Label: RSV group; Type: EXPERIMENTAL; Interventions: Biological: RSV vaccine GSK3003891A | Arm Label: Boostrix group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Boostrix | Intervention Type: BIOLOGICAL; Name: RSV vaccine GSK3003891A; Assigned to Arm(s): RSV group | Intervention Type: BIOLOGICAL; Name: Boostrix; Assigned to Arm(s): Boostrix group
C: Arm Label: RSV LID cp ΔM2-2 Vaccine; Type: EXPERIMENTAL; Interventions: Biological: RSV LID cp ΔM2-2 Vaccine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: RSV LID cp ΔM2-2 Vaccine; Assigned to Arm(s): RSV LID cp ΔM2-2 Vaccine | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: MEDI-534 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: MEDI-534 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Biological: MEDI-534 | Intervention Type: BIOLOGICAL; Name: MEDI-534; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: MEDI-534; Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: MEDI-534; Assigned to Arm(s): 3

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events
Brief Summary: The purpose of this study is to evaluate the effects of cinacalcet (cinacalcet HCl or Sensipar®/Mimpara®) on cardiovascular events and death in chronic kidney disease (CKD) patients with secondary hyperparathyroidism (HPT) who are receiving dialysis.


Options:
A: Arm Label: Standard of care; Type: NO_INTERVENTION; Interventions: Other: Standard of care | Arm Label: Cinacalcet; Type: OTHER; Interventions: Drug: cinacalcet | Intervention Type: DRUG; Name: cinacalcet; Assigned to Arm(s): Cinacalcet | Intervention Type: OTHER; Name: Standard of care; Assigned to Arm(s): Standard of care
B: Intervention Type: DRUG; Name: Cinacalcet HCl; Assigned to Arm(s): N/A
C: Arm Label: IV Paricalcitol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paricalcitol | Arm Label: Cinacalcet (at sites with IV paricalcitol); Type: ACTIVE_COMPARATOR; Interventions: Drug: Cinacalcet | Arm Label: Oral paricalcitol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paricalcitol | Arm Label: Cinacalcet (at sites with oral paricalcitol); Type: ACTIVE_COMPARATOR; Interventions: Drug: Cinacalcet | Intervention Type: DRUG; Name: Paricalcitol; Assigned to Arm(s): IV Paricalcitol, Oral paricalcitol | Intervention Type: DRUG; Name: Cinacalcet; Assigned to Arm(s): Cinacalcet (at sites with IV paricalcitol), Cinacalcet (at sites with oral paricalcitol)
D: Arm Label: Cinacalcet; Type: EXPERIMENTAL; Interventions: Drug: Cinacalcet | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Cinacalcet; Assigned to Arm(s): Cinacalcet | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Quite Smoking Program for Lung Cancer Patients' Families
Brief Summary: The purpose of this study is to evaluate the impact of delivering a coping-focused intervention as an adjunct to a self-help program to promote smoking cessation among relatives of lung cancer patients.


Options:
A: Arm Label: Basic Internet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Basic Internet | Arm Label: Enhanced Internet; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Internet | Arm Label: Enhanced Internet plus Phone; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Internet + phone | Intervention Type: BEHAVIORAL; Name: Basic Internet; Assigned to Arm(s): Basic Internet | Intervention Type: BEHAVIORAL; Name: Enhanced Internet; Assigned to Arm(s): Enhanced Internet | Intervention Type: BEHAVIORAL; Name: Enhanced Internet + phone; Assigned to Arm(s): Enhanced Internet plus Phone
B: Intervention Type: BEHAVIORAL; Name: Coping-focused counseling telephone calls; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: smoking cessation intervention; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: counseling intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: internet-based intervention; Assigned to Arm(s): N/A
D: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Smoking cessation | Arm Label: Simultaneous; Type: EXPERIMENTAL; Interventions: Behavioral: Weight gain prevention and smoking cessation | Arm Label: Sequential; Type: EXPERIMENTAL; Interventions: Behavioral: Weight gain prevention and smoking cessation | Intervention Type: BEHAVIORAL; Name: Weight gain prevention and smoking cessation; Assigned to Arm(s): Sequential, Simultaneous | Intervention Type: BEHAVIORAL; Name: Smoking cessation; Assigned to Arm(s): Control

Answer: B